The method of treatment of acute respiratory viral infections in children

 

(57) Abstract:

The invention relates to medicine and can be used for the treatment of acute viral respiratory infections (ARI) in children. The essence of the invention: for the treatment of influenza and/or parainfluenza in heavy or moderate form in addition to the basic therapy is prescribed Viferon. At the age of 1 - 2 years at a dose of 150,000 IU (Viferon-1), ages 3 - 6 years of age in a dose of 500,000 IU (Viferon-2) and at age 7 - 14 years of age - dose 1000000 IU (Viferon-3). Enter it in 5 days, 2 times a day. The claimed method allows to reduce the treatment time, reduce the number of complications pronounced protective effect. 3 C.p. f-crystals, 5 PL.

The invention relates to medicine and can be used for the treatment of acute viral respiratory infections (ARI) in children.

Viral respiratory infections, including influenza occupy a leading place in the structure of infectious morbidity and huge socio - economic losses. The children suffer from colds more often than adults, the frequency of severe and complicated forms of the disease have significantly more. In addition, these diseases have a negative impact on the health of children and their development. To increase effective gneissic factors antiviral defense.

According to the literature and our research, the production of IFN in children is reduced, especially in the age of 1-7 years. Against the background of current infection (influenza and other ARVI) observed a significant decrease in the concentration of IFN in the blood and the ability of cells to the formation of IFN [1-6].

There is a method of treatment of ARI in children, including basic therapy and the introduction of IFN (reaferona) by inhalation. In this way the drug is administered in aerosol form using a special steam-oxygen chamber in which is maintained a temperature of 28-32 degrees with 100% humidity 40-50 % oxygen, steam and without it. The size of aerosol particles in the chamber ranges from 0.6 to 20 μm. Dose for aerosol application is 20000 IU/kg of body weight per inhalation increased by a factor of losses in the cell depending on age: for children under the age of 5 months, the value of the coefficient is equal to 5, from 6 months to 2 years - 4 and from 3 to 5 years - 3. The treatment begins in the first 3 days of illness and spend the next 4-6 days (the average rate of 5.5 days) 1-2 inhalations per day [3].

However, this method has several disadvantages:

the possibility of side reacting dosing of the drug due to the lack of official inhalation mixtures.

The essence of the invention is that a method of treatment of ARI in children by introducing Viferon in the form of suppositories for children aged 1-3 years in a dose of 150000 ME (Viferon-1), at the age of 3-7 years in a dose of 500,000 IU (Viferon-2) and aged 7-14 dose 1000000 ME (Viferon-3) within 5 days 2 times a day.

Viferonnew antiviral and immunomodulatory drug, produced in the form of suppositories containing recombinant interferon alpha 2 (IFN -2) and membrane components in therapeutically effective doses. The drug is available in three versions which differ by the amount included in its composition of recombinant IFN: Viferon-1 contains 150000 ME IFN in one candle, Viferon-2 contains 500000 ME in one candle and Viferon-3 - 1000000 ME in one candle.

All options Viferon contain-tocopherol acetate (vitamin E) and ascorbic acid (vitamin C) in therapeutically effective doses (RF Patent N 2024253).

Previously Viferon for the treatment of ARI in children has not been used.

The essential features of the proposal are dose and mode of administration, giving the opportunity to get a new result is to reduce the treatment time, reduce the number of complications and subsequent SARS.

ptx2">

When applying the inventive method in the relevant age groups produced the following results:

1. The clinical effect is a reduction in the duration of febrile period and more rapid relief of symptoms of intoxication, as well as fewer complications and their duration.

2. Economic effect - the reduction in the duration of inpatient treatment for 1.5 days.

3. Favorable effect on interferon status - increased levels of circulating serum IFN adequate to disease variables and stimulation interferoninducible ability of leukocytes.

4. The protective effect is a reduction in the frequency of viral and bacterial complications and subsequent SARS.

Considering the results of the research, it was recommended that: children 1-3 years Viferon-1 (150 thousand ME), 3-7 years Viferon-2 (500 thousand ME), 7-14 years Viferon-3 (1 million ME)

The invention is illustrated in the table. 1, 2 and 3 and is illustrated by the following examples.

Example 1. Voit A., 1, 4 months. Clinical diagnosis of influenza, the intermediate form, obstructive syndrome.

Did 16.12.97 at the end of the 1st day of the disease. Ill acutely: lethargy, refusal to eat, fever up to 37,6oC, shortness of breath, to the crimes-heavy: sluggish, geodynamical, no appetite, pale, cyanosis periorbital and nasolabial triangle, fever up to 38oC, unproductive cough, expiratory dyspnea, BH 48 min, tachycardia - 130 beats per minute, AD= 92/60 mm RT.art., in the lungs - breathing hard, dry wheezing. Diferentiate (Viferon-1) was started 5 hours after admission and was in addition to the basic (heavy drinking regime, mukaltin, suprastin, 1% aminophylline in medicine, ultrasonic inhalations with soda solution and aminophylline).

IFN-status to example 1, see table. 4.

Tonormalized on day 2 of hospital stay, obstructive syndrome was arrested also on the 2nd day, the cough became softer after 1.5 days, and less with the 3rd. After 4 days after admission condition is evaluated to be satisfactory. Discharged 20.12.97.

Fast relief of clinical signs (To, cough) and the normalization of the General condition in the infant from the group FIC with reduced start-up performance of the IFN system can be associated with the early appointment of VETERINARII in adequate dose.

Example 2. Pelevin Yaroslav, 4 years. Clinical diagnosis: mixed viral infection (flu+ - paragraphi, hyperthermia, respiratory symptoms (runny nose, "barking" cough, hoarseness), the bottoms of the I degree. In the blood: leukocytosis, mild neutrophilia. In IFN-status: decrease of all parameters. Assigned to combined therapy, including penicillin, 100 mg/kg/day/m, ultrasonic inhalations, mucolytics. However, the child was left without positive dynamics. 9.12.98 made the correction therapy - appointed Viferon-2 with a double introduction. The total duration of febrile period was 3 days, croup syndrome was arrested on the second day, the 4th day condition assessed as satisfactory and the child was discharged home. When the extract was investigated IFN-status, which recorded increases in serum IFN and interferon response of leukocytes. The child was conducted follow-up monitoring within 1 year. After recovery within 6 months the boy was sick and in the next 6 months suffered from two acute respiratory disease in a mild form.

Example 3. Sobolev Cyril, 13 years. Clinical diagnosis: influenza, severe, obstructive syndrome, NAM II. Was admitted in serious condition. From the anamnesis of the disease it is known that the child was sick 2 days ago spicy poyavilas due to severe intoxication syndrome (hyperthermia, reduced overall locomotor activity, impaired microcirculation of the skin in the form of pallor of the skin), respiratory syndrome, expiratory dyspnea, presence of dry rales in all departments of the lungs. In the analysis of blood from 21.11.99 - eosinophilia, accelerated ESR. The etiology of the disease is influenza. From the first day of hospital stay, the child was assigned to combined therapy - basic (antibacterial, pathogenetic, symptomatic) and Viferon-3 (1 million ME). On the third day, the boy has improved due to the relief of obstructive syndrome, decrease intoxication syndrome.

Indicators of IFN-status see table. 5.

With the recovery on the 8th day the boy was discharged home. In follow-up at 3 months was not sick with the flu.

Thus, from the presented data it follows that the claimed method has several advantages:

the clinical effect is a reduction in the duration of febrile period and more rapid relief of symptoms of intoxication, as well as fewer complications and their duration,

economic effect - the reduction in the duration of inpatient treatment for 1.5 days,

favorable effect on interferon status - enhancing zirconate leukocytes,

the protective effect is a reduction in the frequency of viral and bacterial complications and subsequent SARS.

References

1. Bezrukov K. Y. Clinical value of determination of parameters of the system of interferon in acute respiratory viral infections in children. Abstract of Cand.the honey.Sciences. M. 1989

2. Kazakhs T. B., Rumin And. And. and other state of the IFN system in newborn infants and their mothers. Materials Of Scientifically Conference.Congress of obstetricians and gynecologists, Chelyabinsk, 1992, page 255.

3. Kistenev L. B. Clinical and pathogenetic value of IFN in children with acute respiratory viral diseases that occur with obstructive syndrome, and the use of reaferona in complex therapy. Diss. Kida. the honey. Sciences. M. 1997 (prototype).

4. Malinovskaya centuries Age-related features of interferon. Abstract of Prof. Biol.Sciences. M. 1985.

5. Malinovskaya centuries Ontogeny of the IFN system and principles on the use of IFN in practical pediatric practice. In:"Modern aspects of the use of interferon and other immune modulators M. 1990, S. 70-71.

6. Malinovskaya centuries, Bezrukov K. Yu and other System interferon in acute respiratory viral infections in infants and correduria in severe or moderate to severe form in children, including basic therapy and the introduction of recombinant interferon Alfa-2, characterized in that this drug is used Viferon in the form of suppositories containing the interferon dose of 150,000 to 1,000,000 IU and enter it 2 times a day for 5 days in a dose-dependent age.

2. The method according to p. 1, characterized in that children aged 1 - 2 years to impose Viferon containing 150000 IU of interferon (Viferon-1).

3. The method according to p. 1, characterized in that children aged 3 - 6 years imposed Viferon containing 500000 IU of interferon (Viferon-2).

4. The method according to p. 1, characterized in that at the age of 7 - 14 years imposed Viferon containing 1000000 IU of interferon (Viferon-3).

 

Same patents:

The invention relates to medicine and relates to a method of treatment of viral hepatitis In

The invention relates to new phosphonolipids carboxylic acids of formula I and their salts, where R1denotes a linear alkyl WITH9-C13, R2denotes a linear alkyl WITH8-C12, R3denotes hydrogen, a linear alkyl WITH1-C6or benzyl, n = 0-2, 0-3 m, which have antiviral activity and can find application in medicine

The invention relates to biochemistry, namely to obtain biologically active substances with antiviral activity

The invention relates to medicine, in particular to pharmacology relates to antiviral agents in the form of solid dosage forms containing acyclovir, microcrystalline cellulose, salt of stearic acid, low molecular weight polyvinylpyrrolidone, and, optionally, a dye in a certain ratio, and method of its production

The invention relates to pharmaceutical industry, production of medicines intended to treat herpes infections of the skin and mucous membranes

The invention relates to medicine and can be used for selective destruction of cells infected with RNA of hepatitis C virus(HCV)
The invention relates to medicine
The invention relates to medicine, namely to pulmonology, and can be used for the formation of early fibrothorax after pneumonectomy

The invention relates to the field of medicine
The invention relates to medicine, namely to surgery, and can be used for the treatment of acute lung abscess complicated by pyopneumothorax
The invention relates to the pharmaceutical industry, specifically to the mixture of active ingredients and dosage form based on them, which can find use for the treatment of colds

The invention relates to the field of organic chemistry and medicine and relates to new quinoline derivatives of General formula I, where R represents unsubstituted C1-C3-alkyl or C2-C3alkenyl; R1is cyano, which are agonists alpha-2-adrenergic receptors and can be used when obtaining drugs suitable for the treatment of nasal congestion, glaucoma, diarrhea, asthma

The invention relates to the field of organic chemistry and medicine and relates to new quinoline derivatives of General formula I, where R represents unsubstituted C1-C3-alkyl or C2-C3alkenyl; R1is cyano, which are agonists alpha-2-adrenergic receptors and can be used when obtaining drugs suitable for the treatment of nasal congestion, glaucoma, diarrhea, asthma
The invention relates to urology and is intended for the integrated treatment endourethral warts
Up!